The expression pattern of PFKFB3 enzyme distinguishes between induced-pluripotent stem cells and cancer stem cells

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29753-29770

  Cieslar Pobuda, Artur ^a,b   Jain, Mayur Vilas ^a   Kratz, Gunnar ^a,c   Rzeszowska Wolny, Joanna ^b   Ghavami, Saeid ^d   Wiechec, Emilia ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^c County of östergötland ^*  (Sweden)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cancer stem cells; Induced pluripotent stem cells; PFK1; PFKFB3; R point

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; 6 PHOSPHOFRUCTOKINASE; ALDEHYDE DEHYDROGENASE; PFKFB3 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER STEM CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FIBROBLAST; G2 PHASE CELL CYCLE CHECKPOINT; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLIC REGULATION; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL CULTURE; CELL CYCLE; CONFOCAL MICROSCOPY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOBLOTTING; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MULTICELLULAR SPHEROID; NEOPLASM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; CELL CYCLE; CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; INDUCED PLURIPOTENT STEM CELLS; MICROSCOPY, CONFOCAL; NEOPLASMS; NEOPLASTIC STEM CELLS; PHOSPHOFRUCTOKINASE-1; PHOSPHOFRUCTOKINASE-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SPHEROIDS, CELLULAR;

EID: 84945137303     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4995     Document Type: Article

References (57)

1. Takahashi K, Yamanaka S. Induced pluripotent stem cells in medicine and biology. Development. 2013; 140:2457-2461.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131:861-872.
3. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S. Variation in the safety of induced pluripotent stem cell lines. Nature biotechnology. 2009; 27:743-745.
4. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M, Real PJ, Macia A, Sanchez L, Ligero G, Garcia-Parez JL, Menendez P. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem cells. 2010; 28:1568-1570.
5. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008; 40:499-507.
6. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2011; 71:1772-1780.
7. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochemical and biophysical research communications. 2009; 383:157-162.
8. Nagata S, Hirano K, Kanemori M, Sun LT, Tada T. Selfrenewal and pluripotency acquired through somatic reprogramming to human cancer stem cells. PloS one. 2012; 7:e48699.
9. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006; 66:1883-1890. discussion 1895-1886.
10. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414:105-111.
11. Hombach-Klonisch S, Paranjothy T, Wiechec E, Pocar P, Mustafa T, Seifert A, Zahl C, Gerlach KL, Biermann K, Steger K, Hoang-Vu C, Schulze-Osthoff K, Los M. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Archivum immunologiae et therapiae experimentalis. 2008; 56:165-180.
12. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem cells. 2009; 27:1050-1056.
13. Ghule PN, Medina R, Lengner CJ, Mandeville M, Qiao M, Dominski Z, Lian JB, Stein JL, Van Wijnen AJ, Stein GS. Reprogramming the Pluripotent Cell Cycle: Restoration of an Abbreviated G1 Phase in Human Induced Pluripotent Stem (iPS) Cells. J Cell Physiol. 2011; 226:1149-1156.
14. Wasik AMGJ, Pantovic A, Cieslar-Pobuda A, Asgari HR, Bundgaard-Nielsen C, Rafat M, Dixon IMC, Ghavami S, Los MJ. Reprogramming and carcinogenesis-parallels and distinctions. Int Rev Cell Mol Biol. 2014; 308.
15. Harper LJ, Costea DE, Gammon L, Fazil B, Biddle A, Mackenzie IC. Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC cancer. 2010; 10:166.
16. Baserga R. Oncogenes and the strategy of growth factors. Cell. 1994; 79:927-930.
17. Campisi J, Medrano EE, Morreo G, Pardee AB. Restriction point control of cell growth by a labile protein: evidence for increased stability in transformed cells. Proceedings of the National Academy of Sciences of the United States of America. 1982; 79:436-440.
18. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell cycle. 2002; 1:103-110.
19. Colombo SL, Palacios-Callender M, Frakich N, Carcamo S, Kovacs I, Tudzarova S, Moncada S. Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. Proc Natl Acad Sci U S A. 2011; 108:21069-21074.
20. Tudzarova S, Colombo SL, Stoeber K, Carcamo S, Williams GH, Moncada S. Two ubiquitin ligases, APC/CCdh1 and SKP1-CUL1-F (SCF)-beta-TrCP, sequentially regulate glycolysis during the cell cycle. Proc Natl Acad Sci U S A. 2011; 108:5278-5283.
21. Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med. 2013; 45:e45.
22. Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, Polak K, Tondera D, Gounarides J, Yin H, Zhou F, Green MR, Chen L, Monti S, Marto JA, Shipp MA, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer cell. 2012; 22:547-560.
23. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, Rajagopalan KN, Maddie M, Vemireddy V, Zhao Z, Cai L, Good L, Tu BP, Hatanpaa KJ, Mickey BE, Mates JM, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012; 15:827-837.
24. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-314.
25. Marie SK, Shinjo SM. Metabolism and brain cancer. Clinics (Sao Paulo). 2011; 66:33-43.
26. Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatases in cancer. Experimental and molecular pathology. 2009; 86:174-179.
27. Kessler R, Bleichert F, Warnke JP, Eschrich K. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas. Journal of neuro-oncology. 2008; 86:257-264.
28. Novellasdemunt L, Obach M, Millan-Arino L, Manzano A, Ventura F, Rosa JL, Jordan A, Navarro-Sabate A, Bartrons R. Progestins activate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in breast cancer cells. Biochem J. 2012; 442:345-356.
29. Calvo MN, Bartrons R, Castano E, Perales JC, Navarro-Sabate A, Manzano A. PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. FEBS letters. 2006; 580:3308-3314.
30. Klarer AC, O'Neal J, Imbert-Fernandez Y, Clem A, Ellis SR, Clark J, Clem B, Chesney J, Telang S. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer & metabolism. 2014; 2:2.
31. Pardee AB. G1 events and regulation of cell proliferation. Science. 1989; 246:603-608.
32. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, Los M. Cancer stem cell markers in common cancers-therapeutic implications. Trends in molecular medicine. 2008; 14:450-460.
33. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell stem cell. 2007; 1:555-567.
34. Ghebeh H, Sleiman GM, Manogaran PS, Al-Mazrou A, Barhoush E, Al-Mohanna FH, Tulbah A, Al-Faqeeh K, Adra CN. Profiling of normal and malignant breast tissue show CD44 high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC cancer. 2013; 13:289.
35. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:3983-3988.
36. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast cancer research: BCR. 2008; 10:R25.
37. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell stem cell. 2009; 5:237-241.
38. Minchenko O, Opentanova I, Minchenko D, Ogura T, Esumi H. Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation. FEBS letters. 2004; 576:14-20.
39. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, Lane A, Trent JO, Chesney J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008; 7:110-120.
40. Bando H, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C, Yoshioka N, Bucala R, Koike T. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11:5784-5792.
41. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R, Bucala R. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2, PFKFB3) in human cancers. Cancer Res. 2002; 62:5881-5887.
42. Duran J, Obach M, Navarro-Sabate A, Manzano A, Gomez M, Rosa JL, Ventura F, Perales JC, Bartrons R. Pfkfb3 is transcriptionally upregulated in diabetic mouse liver through proliferative signals. The FEBS journal. 2009; 276:4555-4568.
43. Almeida A, Bolanos JP, Moncada S. E3 ubiquitin ligase APC/C-Cdh1 accounts for the Warburg effect by linking glycolysis to cell proliferation. Proc Natl Acad Sci U S A. 2010; 107:738-741.
44. Becker KA, Stein JL, Lian JB, van Wijnen AJ, Stein GS. Human embryonic stem cells are pre-mitotically committed to self-renewal and acquire a lengthened G1 phase upon lineage programming. Journal of cellular physiology. 2010; 222:103-110.
45. Mannello F. Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm. BMC Med. 2013; 11:169.
46. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, Chesney J. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene. 2006; 25:7225-7234.
47. Mor I, Cheung EC, Vousden KH. Control of glycolysis through regulation of PFK1: old friends and recent additions. Cold Spring Harb Symp Quant Biol. 2011; 76:211-216.
48. Obach M, Navarro-Sabate A, Caro J, Kong X, Duran J, Gomez M, Perales JC, Ventura F, Rosa JL, Bartrons R. 6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. The Journal of biological chemistry. 2004; 279:53562-53570.
49. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002; 277:23111-23115.
50. Bobarykina AY, Minchenko DO, Opentanova IL, Moenner M, Caro J, Esumi H, Minchenko OH. Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. Acta Biochim Pol. 2006; 53:789-799.
51. Kawano Y, Kikukawa Y, Fujiwara S, Wada N, Okuno Y, Mitsuya H, Hata H. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells. International journal of oncology. 2013; 43:1809-1816.
52. Muz B, de la Puente P, Azab F, Luderer M, Azab AK. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer J. 2014; 4:e262.
53. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell cycle. 2009; 8:3274-3284.
54. Telang S, Clem BF, Klarer AC, Clem AL, Trent JO, Bucala R, Chesney J. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation. J Transl Med. 2012; 10:95.
55. Sweet S, Singh G. Accumulation of human promyelocytic leukemic (HL-60) cells at two energetic cell cycle checkpoints. Cancer Res. 1995; 55:5164-5167.
56. Rakar J, Lonnqvist S, Sommar P, Junker J, Kratz G. Interpreted gene expression of human dermal fibroblasts after adipo-, chondro-and osteogenic phenotype shifts. Differentiation; research in biological diversity. 2012; 84:305-313.
57. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.